26-A-13550-ACC EFFECTIVENESS OF A BIVALENT RSV PREFUSION F PROTEIN-BASED VACCINE AMONG PERSONS WITH AND WITHOUT DIABETES: A PRESPECIFIED ANALYSIS OF THE DAN-RSV TRIAL

Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

M

Mats Højbjerg Lassen

N

Niklas Dyrby Johansen

S

Sine Hoejlund Christensen

N

Negar Aliabadi

Pfizer Inc, New York, New York

K

Kristoffer Grundtvig Skaarup

University of Copenhagen

S

Scott Solomon

Harvard Medical School, Division of Cardiovascular Medicine, Brigham and Women’s Hospital , Boston, MA , USA

J

Jens-Ulrik Staehr Jensen

Pfizer Inc, New York, New York

Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, New York, New York, USA.

T

Tor Biering-Sorensen

Cite This Article

Manan Pareek, Mats Højbjerg Lassen, Niklas Dyrby Johansen, et al. (2026). 26-A-13550-ACC EFFECTIVENESS OF A BIVALENT RSV PREFUSION F PROTEIN-BASED VACCINE AMONG PERSONS WITH AND WITHOUT DIABETES: A PRESPECIFIED ANALYSIS OF THE DAN-RSV TRIAL. Journal of the American College of Cardiology, 87(13), A308-A309. https://doi.org/10.1016/j.jacc.2026.02.763

26-A-13550-ACC EFFECTIVENESS OF A BIVALENT RSV PREFUSION F PROTEIN-BASED VACCINE AMONG PERSONS WITH AND WITHOUT DIABETES: A PRESPECIFIED ANALYSIS OF THE DAN-RSV TRIAL

You May Also Like